Your session is about to expire
← Back to Search
SAF312 for Chronic Ocular Pain
Study Summary
This trial is designed to study the safety and effectiveness of two concentrations of an eye drop medication in people who still have corneal problems four months after surgery. The goal is to also find the optimal dose of the medication to continue development.
- Chronic Ocular Pain
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 40 Patients • NCT02961062Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has SAF312 been granted approval by the US Food and Drug Administration?
"Due to the lack of efficacy data and presence of safety data, our team assigned SAF312 a score of 2 on a scale from 1-3."
To what extent is enrollment being offered for this clinical trial?
"Affirmative. Clinicaltrials.gov attests that this scientific trial is currently recruiting participants, the initial post being on April 21st 2021 and last revised November 3rd 2022. 150 volunteers are needed from 31 distinct locations to participate in this study."
Is enrollment in this trial still available?
"The data on clinicaltrials.gov affirms that this trial is actively enrolling participants, with the initial posting being made April 21st 2021 and most recent edits occurring November 3rd 2022."
In what count of medical centers is this research experiment being conducted?
"Currently, 31 medical facilities in cities such as Bellaire, Smyrna and Oklahoma City are running this trial. It is recommended that prospective participants choose the clinic closest to them to avoid extensive travel needs if they decide to enroll."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger